Wire · operational-macro
FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The FDA approved adrabetadex (Lembaz) as the first therapy shown to extend survival in infantile-onset Niemann-Pick disease type C (I-NPC) patients weighing at least 7 kg, reducing mortality risk by 55%. The intrathecal treatment addresses CNS cholesterol accumulation but carries risks including irreversible hearing loss requiring close audiometric monitoring.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.
◆ ◆ The Wire takeaway
You can enter the rare pediatric neurodegenerative space now that adrabetadex has set a survival benchmark with FDA approval. Test clinics and advocacy groups will be open doors for early users, but manage hearing risks tightly to keep patients on treatment.
◆ Coverage
3 sources · 17 Nov 2026
◆ Related on Wire
◆ Topics